Condition: Pemphigus Vulgaris · Sponsor: Jinbo Chen
This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
This description comes directly from the study's public registry record.
Jinbo Chen, MD, PhD · +86 188 2736 3048 · chen999jb@163.com
Xiaoya Du · +86 27 8533 2028
Always discuss trial participation with your own doctor first.
| Traditional Chinese and Western Medicine Hospital of Wuhan, Wuhan, Hubei | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07681388